RT Journal Article
SR Electronic
T1 Transcriptome-Wide Association Analysis Identifies Novel Candidate Susceptibility Genes for Prostate-Specific Antigen Levels in Men Without Prostate Cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.04.23289526
DO 10.1101/2023.05.04.23289526
A1 Chen, Dorothy M.
A1 Dong, Ruocheng
A1 Kachuri, Linda
A1 Hoffmann, Thomas
A1 Jiang, Yu
A1 Berndt, Sonja I.
A1 Shelley, John P.
A1 Schaffer, Kerry R.
A1 Machiela, Mitchell J.
A1 Freedman, Neal D.
A1 Huang, Wen-Yi
A1 Li, Shengchao A.
A1 Lilja, Hans
A1 Van Den Eeden, Stephen K.
A1 Chanock, Stephen
A1 Haiman, Christopher A.
A1 Conti, David V.
A1 Klein, Robert J.
A1 Mosley, Jonathan D.
A1 Witte, John S.
A1 Graff, Rebecca E.
YR 2023
UL http://medrxiv.org/content/early/2023/05/05/2023.05.04.23289526.abstract
AB Deciphering the genetic basis of prostate-specific antigen (PSA) levels may improve their utility to screen for prostate cancer (PCa). We thus conducted a transcriptome-wide association study (TWAS) of PSA levels using genome-wide summary statistics from 95,768 PCa-free men, the MetaXcan framework, and gene prediction models trained in Genotype-Tissue Expression (GTEx) project data. Tissue-specific analyses identified 41 statistically significant (p < 0.05/12,192 = 4.10e-6) associations in whole blood and 39 statistically significant (p < 0.05/13,844 = 3.61e-6) associations in prostate tissue, with 18 genes associated in both tissues. Cross-tissue analyses that combined associations across 45 tissues identified 155 genes that were statistically significantly (p < 0.05/22,249 = 2.25e-6) associated with PSA levels. Based on conditional analyses that assessed whether TWAS associations were attributable to a lead GWAS variant, we found 20 novel genes (11 single-tissue, 9 cross-tissue) that were associated with PSA levels in the TWAS. Of these novel genes, five showed evidence of colocalization (colocalization probability > 0.5): EXOSC9, CCNA2, HIST1H2BN, RP11-182L21.6, and RP11-327J17.2. Six of the 20 novel genes are not known to impact PCa risk. These findings yield new hypotheses for genetic factors underlying PSA levels that should be further explored toward improving our understanding of PSA biology.Competing Interest StatementJSW is a non-employee, cofounder of Avail Bio. HL is named on a patent for assays to measure intact prostate-specific antigen and a patent for a statistical method to detect prostate cancer commercialized by OPKO Health (4KScore). HL receives royalties from sales of the assay and has stock in OPKO Health. HL serves on the Scientific Advisory Board for Fujirebio Diagnostics Inc and owns stock in Diaprost AB and Acousort AB.Funding StatementThe Precision PSA study is supported by funding from the National Institutes of Health (NIH) and National Cancer Institute (NCI) under award number R01CA241410 (PI: JSW). REG is supported by a Prostate Cancer Foundation Young Investigator Award. LK is supported by funding from National Cancer Institute (R00CA246076). JPS is supported by funding from the National Institute of General Medical Sciences (T32GM007347). HL is supported in part by funding from NIH/NCI (P30-CA008748, U01-CA199338, R01CA244948) and the Swedish Cancer Society (Cancerfonden 20 1354 PjF). RK is supported by funding from the NIH (R01 CA244948 and R01 CA175491).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of University of California, San Francisco gave ethnical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesGWAS summary statistics used in this analysis are available for download from Kachuri et al are available from the following Zenodo repository: https://doi.org/10.5281/zenodo.7460134. Transcriptome prediction weights and models used for MetaXcan analyses are available from: https://predictdb.org. https://doi.org/10.5281/zenodo.7460134 https://predictdb.org